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The association of genetic variation with disease and drug response, and improvements in nucleic acid technologies, have given great optimism for the impact of 'genomic medicine'. However, the formidable size of the diploid human genome 1 , approximately 6 gigabases, has prevented the routine application of sequencing methods to deciphering complete individual human genomes. To realize the full potential of genomics for human health, this limitation must be overcome. Here we report the DNA sequence of a diploid genome of a single individual, James D. Watson, sequenced to 7.4-fold redundancy in two months using massively parallel sequencing in picolitre-size reaction vessels. This sequence was completed in two months at approximately onehundredth of the cost of traditional capillary electrophoresis methods. Comparison of the sequence to the reference genome led to the identification of 3.3 million single nucleotide polymorphisms, of which 10,654 cause amino-acid substitution within the coding sequence. In addition, we accurately identified smallscale (2-40,000 base pair (bp)) insertion and deletion polymorphism as well as copy number variation resulting in the large-scale gain and loss of chromosomal segments ranging from 26,000 to 1.5 million base pairs. Overall, these results agree well with recent results of sequencing of a single individual 2 by traditional methods. However, in addition to being faster and significantly less expensive, this sequencing technology avoids the arbitrary loss of genomic sequences inherent in random shotgun sequencing by bacterial cloning because it amplifies DNA in a cell-free system. As a result, we further demonstrate the acquisition of novel human sequence, including novel genes not previously identified by traditional genomic sequencing. This is the first genome sequenced by next-generation technologies. Therefore it is a pilot for the future challenges of 'personalized genome sequencing'.
To catalogue the genomic diversity within a single individual, a total of 106.5 million high-quality reads were generated by 454-sequencing 3 , representing approximately 24.5 billion DNA bases. Reads that aligned to the genome were further filtered using stringent criteria to ensure the accuracy of mapping, resulting in 93.2 million reads aligned to reference genome sequence. The reference genome sequence was thus covered to an average depth of 7.4-fold (Fig. 1a) . The alignments between the uniquely mapped reads and the reference genome were used to catalogue genetic variation in the subject's DNA, including single nucleotide polymorphisms (SNPs), small insertions and deletions (indels), and copy number variation (CNV).
The 454 base-calling software provides error estimates (Q values) for each base. We developed a three-step filtering process using the patterns of error and associated Q values from the 454 base-calling software to improve the accuracy of SNP discovery. An initial 14 million variant positions were filtered to 3.32 million putative SNPs (Table 1) .
Comparison of these putative SNPs in the subject's genome with those in the dbSNP (dbSNP: http://www.ncbi.nlm.nih.gov/ projects/SNP/) revealed 2.72 million in common ('known SNPs'). Approximately 99% of SNPs in dbSNP are bi-allelic. At only 10,425 positions did the subject's variant not match the variant found in dbSNP. Although some of these could represent a third allele in the population, or an error in the dbSNP polymorphism record, we conservatively estimated the false discovery rate in the known SNPs to be approximately 0.38% based on the mismatches with dbSNP.
The remaining 0.61 million SNPs were at positions not previously identified as polymorphic in dbSNP ('novel SNPs'). The known SNPs were divided almost equally between homozygous (50.2%) and heterozygous (49.8%) SNPs, whereas within the novel SNPs heterozygotes predominate (83.3%) compared with homozygotes (16.7%). Because most common alleles in human populations are already captured in dbSNP, novel variants are expected to be rare, and therefore much more likely to be found as heterozygotes.
We assessed the accuracy of the known SNPs derived from DNA sequencing by comparison with the experimental genotyping of the subject's DNA using an Affymetrix 500K microarray. Compared with a haploid reference sequence, there are four possible outcomes of SNP array genotyping: homozygous for the reference allele; homozygous for the variant (non-reference) allele; heterozygous; and assay failure. Table 2 shows the results for 494,713 markers that were successfully genotyped. The subject's DNA sequence exhibited only the reference allele at 99.4% of the markers homozygous for the reference and at 95.1% of markers homozygous for the variant. Genotyping identified 135,413 heterozygous markers of which 75.8% exhibited two alleles in the 454-reads. The lower sensitivity of detection of heterozygotes is predicted by a Poisson process of sampling DNA fragments modelled on a diploid genome (Methods). Consistent with this model, the coverage was lower at the 24.2% of heterozygous positions where DNA sequencing represented only one of the correct alleles ( Fig. 1b and Supplementary Table 2 ). The Poisson model further shows that 13-fold average coverage would be required to detect 99% of all heterozygous SNPs ( Supplementary Fig. 4 ).
The DNA sequencing genotypes disagree with the SNP array genotyping in 4,948 cases, or 1.0% of the time; another 3,499 markers (0.30%) had no coverage, consistent with the genome-wide redundancy of the sequence. Assuming the sensitivity and specificity of the markers on the microarray is representative of those found throughout the human genome, we estimate the total number of SNPs in the subject's genome to be approximately 3.7 million (see 'Sensitivity and specificity of SNP discovery' in Supplementary Information).
We identified 222,718 indels ranging from 2 to 38,896 bp, with 113,539 in common with indels in dbSNP; 85,418 indels are found as homozygotes, and 137,300 were heterozygotes. Insertions account for 65,677 events, and deletions 157,041. A portion of the deletion size distribution from 2 to 1000 bp is shown in Fig. 1c . The distribution of deletions shows the relative enrichment for events in the range 300-350 bases in length, as expected from the known polymorphism of Alu SINE elements 4, 5 . The size range over which insertions are detected is limited by the length of the reads; in the analysis of our 250 base-pair 454-sequencing reads, the largest observed was 208 bp.
A total of 345 indels were observed to overlap coding sequence and had the potential to alter protein function. We designed primers to amplify and validate by Sanger sequencing 111 of these events with a size range of 3-50 bases. A total of 78 indels were successfully validated of which 66 were observed to be in length multiples of 3, ranging from 3 to 33 bp, and hence not expected to cause protein translation frame shifts. Sixty-five of these indels were found as heterozygotes. Surprisingly, a 4-bp deletion in exon 11 of SGEF was found to be homozygous; however, this gene is highly conserved in vertebrate species from rhesus macaque to stickleback, and all manifest the same 4-bp deletion in their genome ( Supplementary  Fig. 5 ). Furthermore, two other independent human messenger RNAs (mRNAs) harbour the deletion as well, suggesting the subject's allele was the wild type and that the reference harbours a rare insertion.
CNVs are local gains or losses of regions in the genome owing to duplication or deletion that can be associated with genetic disease 6 and which should be detectable by variation in the average DNA sequence coverage of the region. A comparative genomic hybridization (CGH) microarray analysis of the subject's DNA revealed 23 apparent CNV regions ranging in size from 26 kb to 1.6 Mb: 9 with DNA gains and 14 with a loss. The sequence coverage data exhibited a gain or loss congruent with the CGH result at 18 of the 23 regions (Supplementary Table 4 ). Regions of CNV are polymorphic in populations, segregating as alleles with varying frequency 7, 8 . Consequently, the interpretation of a CGH microarray depends on the reference genome with which the subject is compared. This difference in reference standard is unavoidable when comparing CGH with DNA sequencing results using National Center for Biotechnology Information (NCBI) build 36 as the reference, which is not based on a single individual and for which no physical DNA sample exists. We experimentally demonstrated variation in CGH results by repeating the CGH array using a second reference genome and two different array platforms, demonstrating the effect the reference DNA has on the outcome of a CGH experiment (Supplementary Table 4 ).
An individual region of homozygous loss was characterized further using CGH results and DNA sequencing ( Supplementary Fig. 6c ). Sequence alignment of the subject's reads spanning the breakpoint of LETTERS a homozygous deletion region reveals a 2-bp addition at the breakpoint junction, suggesting non-homologous end joining 6 was the mechanism involved in generating the deletion, and demonstrating the feasibility of using 454 sequence reads for identifying CNV breakpoints ( Supplementary Fig. 6c ). Several other CNV regions were flanked by repeats and segmental duplications, and likely occur by non-allelic homologous recombination, as was reported recently for the CNV loss at 22q13.1 (ref. 9) (see CNV 23 in Supplementary  Table 4) .
None of the CNV regions we defined are currently known to be involved in a recognizable phenotype; however, either trait or disease susceptibility correlations could occur in the future 10 . Thirty-four genes are predicted to be affected by these gains and losses, including two separate olfactory receptor groups, several genes with possible roles in cancers of the prostate, breast and colon, a gene from the HLA-D locus, and two proteins thought to be involved in RNA editing (Supplementary Table 4 ).
Among the 3.3 million SNPs found in the subject's genome were 8,996 non-synonymous changes in known SNPs and 1,573 in novel SNPs. We compared the non-synonymous known SNPs with the Human Gene Mutation Database (HGMD), the largest current compendium of human disease alleles 11 . Thirty-two alleles exactly matched mutations reported in the HGMD whereas an additional 310 of these were in HGMD genes but were either alleles or aminoacid positions not previously characterized as disease-causing. In 12 cases the specific alterations and loci consisted of genes where homozygous recessive alleles can give rise to disease or other recognizable phenotype (Table 3) ; and 20 cases are reported to be associations with increased disease risk (Supplementary Table 5 ).
Ten of the 12 alleles in Table 3 are thought to be highly penetrant, Mendelian recessive disease-causing alleles. Seven of ten were heterozygous in the subject's genome sequence; the other three only exhibited one allele but have an average sequence coverage less than fivefold. Because the subject does not have these three diseases, and we expect not to recover the second allele for 24% of heterozygous positions, it is likely that he is not homozygous for these disease allele positions. We note that there are not yet any systematic studies of the population frequencies of these alleles. Nevertheless, the subject is a carrier for ten highly penetrant genetic disease loci found in the HGMD data set consisting of 900 genes. It has been estimated there are fewer than ten lethal equivalents in each person [12] [13] [14] . Because we have drawn ten from an HGMD subset of the genome, we would predict the subject harbours a much greater number of deleterious Mendelian mutant alleles than is commonly estimated.
In addition, a sampling of 3,898 of the non-synonymous SNPs were tested for their possible functional impact on the protein sequence using the software Polyphen 15 . Polyphen classified 7.3% as 'probably damaging', suggesting these changes will be of functional consequence to the protein. The remainder were classified as either 'possibly damaging' (13%) or 'benign' (74%).
The genome sequence of another individual (C. Venter) was recently reported 2 . That study reported a 7.5-fold genome coverage using Sanger reads. The Venter genome harboured approximately 2.8 million known SNPs and about 0.74 million novel SNPs, in close agreement with the results from 454-reads of the Watson genome at a similar fold coverage. The two individuals shared 1.68 million of the SNPs, of which 5,230 were non-synonymous, accounting for 58% of the subject's non-synonymous SNPs. Watson and Venter are each distinguished from the reference by 3,766 and 3,882 nonsynonymous SNPs, respectively, and therefore are different from each other by 7,648 protein coding changes. This is the most comprehensive comparison of the non-synonymous difference between two diploid genomes yet undertaken.
The subject's data also contained 1.5 million reads of novel sequence that did not map to build-36, corresponding to about 1.4% of the total sequence data. Approximately 65% of the unmapped sequences matched to known human repeats enriched for satellite DNA and other repeat elements characteristic of heterochromatin ( Supplementary Fig. 7 ). The novel reads were assembled into approximately 170,000 contigs spanning 48 Mb. After removing contigs with fewer than 100 bp of contiguous unique sequence, 110,000 contigs spanning 29 Mb remained, which is close to the 25 Mb of euchromatic sequence predicted to be absent from the reference genome 1 . These non-repeat contigs closely match to 33 human complementary DNA (cDNA) sequences from a variety of tissues and predicted functions (Supplementary Table 6 ) having no known map location on the human reference genome (see Methods). To assess further the gene-coding potential of these novel DNA sequences, we compared conceptual translations of the contigs greater than 1,000 bp (1,279 in all) with the GenBank non-redundant (NR) protein database. This search yielded 60 significant, but not identical, matches to 49 different proteins in humans and other vertebrates (Supplementary Table 7 ). The annotations of several of these transcripts are consistent with transcription factor or signalling molecules. Therefore it is possible this diploid genome sequence will contribute important new genes to the human genome.
The sequencing method used in this study has many advantages over traditional capillary sequencing. It is inherently scalable, which means that sequencing costs in the miniature continue to decrease and throughput increases as the density of the sequencing reactions on the chip increases, and read lengths get longer 3 . In this study we sequenced the genome of Dr Watson for less than US$1 million, Returning research results to research participants Should the research participant be able to receive information about their individual genome sequence? Considerations. Dr Watson requested that he receive information about all data generated from this research project. Generally, patients have a right to receive medical information, but this right does not typically extend to individual research results. Concerns include validity of genetic tests not performed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory, the unknown clinical significance of much of the generated data, and protecting subjects from potentially harmful information, such as information about genetic risk of uncertain penetrance. These considerations have to be weighed against the ethical principles of respect for autonomy and the right to receive relevant information about oneself, as well as the principle of reciprocity, which suggests a right to receive information in exchange for research participation. Management. The research team felt that because of Dr Watson's unique expertise he would be able to understand adequately the significance and limitations of these data. Therefore, out of respect for his autonomous decision to receive the information, Dr Watson was given his entire genome sequence on a miniature hard drive. Genetic counselling was provided to help with interpretation and to ensure adequate understanding of the information given and the limitations of its clinical significance. It remains controversial whether other research participants who do not share Dr Watson's expertise ought to be informed of individual results of genetic research. Certainly for many, whole-genome data will be meaningless. A more analysed form of the data may therefore be required. Should the research participant be able to request that certain information be redacted before individual and/or public disclosure? Considerations. Although patients generally have a right to receive certain medical information, they can waive that right and request that information be withheld from them. The right not to know of a genetic risk is legally sanctioned but remains ethically controversial. Even if this right is recognized, however, decisions about redactions must be made a priori to preserve the right not to know a particular finding. In the context of whole-genome sequencing research, because genomic information is stable over time but our understanding of the clinical significance of that information continues to grow at a very fast pace, we cannot anticipate future findings that may reveal genetic risk information that the participant may not have wanted to know. We also cannot entirely eliminate the risk that inferences could be made about the missing information from downstream and/or upstream data. 2. In the clinical context, the physician's duty to warn biological relatives of genetic risk remains controversial. In the research context, because the data are not validated in an approved laboratory, the obligation to warn at-risk relatives is even more tenuous. As in the clinic, all research participants should be informed of the risks to relatives and encouraged to discuss research results with them. In this project, genetic counselling was offered for family members, free of charge.
3. There are privacy risks associated with the public release of genomic data for the individual research participant. There are also risks, though of a more uncertain nature, of public release for close biological relatives, especially when the participant is clearly identified and the release of his data is publicized. What obligation, if any, does an investigator have to protect third-party relatives from these privacy risks? Management. Risks to relatives were disclosed and thoroughly discussed with the research participant. He was strongly encouraged to discuss these issues with biological relatives and to make a family decision about research participation and data release. The issue of whether investigators should publicly release Dr Watson's data without familial consent was avoided by presenting the edited genome sequence to Dr Watson who then released it himself directly into publicly accessible databases. This did not alleviate any moral obligation Dr Watson may have to protect his biological relatives from the uncertain privacy risks associated with public data release. It is also unlikely that future research participants will be able to facilitate their own data release, making the question of obligations to third-party relatives a policy priority.
whereas the genome of Venter by Sanger sequence reportedly cost approximately US$100 million. Although not used in this study, this sequencing technology allows the production of mate-paired reads. The use of mate-pair reads will enable assessment of a wider range of indels and other structural rearrangements, and facilitate the incorporation of new sequence into the reference genome 16 . The principal weakness of the method is that it currently does not allow efficient detection of single-base indels in homopolymers. Future developments in chemistry and software will improve the ability to identify single-base indels.
A key aim of personal genome sequencing is to identify genome sequences that may be associated with disease, or are predictive of response to medication. The need to make genotype-phenotype correlations before having predictive value is at the heart of both the excitement and the dilemma of the new era of genomic medicine 17 . Thus the ability to sequence individuals readily using highthroughput, scaleable, low-cost, completely in vitro technology, as demonstrated here, is an important milestone in our ability to connect 'personalized genomes' to 'personalized medicine' and enable these critical correlations to be made.
METHODS SUMMARY
Mapping and alignment to the genome. DNA sequencing on the Genome Sequencer FLX instrument (454, Inc.) is described in detail in Methods. Reads, averaging approximately 250 bases, were mapped on to the human reference genome, NCBI build 36, by sequence alignment using Basic Local Alignment Search Tool (BLAST)-like alignment tool (BLAT). Reads were removed from subsequent analysis that failed to meet minimum criteria (see Methods). Reads that passed the alignment quality criteria were realigned to local reference genome fragments using Cross_match software; the refined alignments were parsed for sequence variation between the subject and the reference. An error model was developed to separate sequencing error from true genomic variation, and the location and type of each putative true variant was tabulated (see Methods). Assembly of non-matching reads. One and a half million reads that failed to find a match in the reference genome sequence ('no-hit' reads) and another 2.2 million reads with low-quality alignments to the reference were pooled for sequence assembly. All reads were trimmed to remove the last 50 bases in which most of the sequencing error lies. Reads less than 50 bases after trimming were discarded. The assembly of the remaining 2.6 million trimmed reads followed the standard ATLAS-WGS procedure 18, 19 . Laboratory analysis of genomic DNA. A DNA sample from the subject was labelled and annealed to the Affymetrix 500K GeneChip array to provide independent laboratory analysis of the subject's SNPs and conformation of the DNA sequencing coverage. To compare local fluctuation in DNA sequencing coverage with copy number variation in the subject's genome, three additional DNA samples were labelled and mixed each in a 1:1 ratio with separately labelled control DNAs. The mixtures were annealed to each of two Agilent 244K array CGH chips and one Nimblegen HD2 chip.
